Evidence map›Paper›PMID 37247110›Full record

ArticleJournal of bone and mineral metabolism2023

Denosumab effect on bone mineral density and urinary-NTX in breast cancer patients receiving aromatase inhibitors.

Masahiro Shibata, Mai Okumura, Shin Kawano, Hirotoshi Noda, Chihiro Toyota, Yutaka Mizuno

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Masahiro ShibataDepartment of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan. m-shibata@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0003-1028-2796
Mai OkumuraDepartment of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Shin KawanoDepartment of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Hirotoshi NodaDepartment of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Chihiro ToyotaDepartment of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Yutaka MizunoDepartment of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Yokkaichi Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAromatase inhibitors are used post-surgical intervention in postmenopausal patients with breast cancer. However, these drugs accelerate decline in bone mineral density (BMD), which is countered by use of denosumab, and the efficacy of the drug can be assessed by bone turnover markers. We investigated the effects of denosumab administration for 2 years on BMD and urinary N-telopeptide of type I collagen (u-NTX) levels in breast cancer patients treated with aromatase inhibitors. MATERIALS AND

methodsThis was a single-center retrospective study. Postoperative hormone receptor-positive breast cancer patients with low T-scores biannually received denosumab from the time of initiation of aromatase inhibitor therapy for 2 years. BMD was measured every 6 months, and u-NTX levels were assessed after 1 month and thereby every 3 months.

resultsThe median patient age of the 55 patients included in this study was 69 (range: 51-90) years. BMD gradually increased in the lumbar spine and femoral neck and u-NTX levels were lowest at 3 months post-initiation of therapy. Patients were divided into two groups based on the change ratio of u-NTX 3 months post-denosumab administration. Of these, the group with higher change ratio showed a higher degree of BMD restoration in the lumbar spine and femoral neck 6 months post-denosumab treatment.

conclusionDenosumab increased BMD in patients treated with aromatase inhibitors. The u-NTX level decreased soon after start of denosumab treatment, and its change ratio is predictive of improvement in BMD.

Indexed as

Bone Density Conservation AgentsBreast NeoplasmsAgedAged, 80 and overAromatase InhibitorsBiomarkersBone DensityDenosumabFemaleHumansLumbar VertebraeMiddle AgedRetrospective StudiesAromatase InhibitorsBiomarkersBone Density Conservation AgentsDenosumabAromatase inhibitorBone mineral densityBreast cancerDenosumabUrinary N-telopeptide of type I collagen (u-NTX)

Identifiers

PMID37247110
OpenAlexW4378640163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.